Scrip Pharma Intelligence: Orphan Drug Pricing

Back Bay Life Science Advisors’ Senior Vice President, Stephan Gauldie was interviewed by Scrip Pharma Intelligence for an article posted on Rare Disease Day, “Scrip Asks… What Will Happen In Orphan Drug Pricing In The Next Five Years?”

At Back Bay, Dr. Gauldie advises clients around building strategic, successful franchises, and positioning around M&A, buy-side diligence and liquidity planning and positioning for emerging growth companies.

Subscribers can view the full article here and everyone can view and share the slide show here.